Monitor for Q1 2026 revenue approaching $1.5M, which would trigger expiration of milestone warrants — a potential near-term catalyst. Track enrollment completion in the TIGeR-PaC trial and conversion of 16 trial sites into commercial customers as key leading indicators of revenue acceleration.
Price Chart
Executive Summary
RenovoRx closed an oversubscribed private placement raising $10 million in gross proceeds through the issuance of 10.6 million shares and revenue milestone warrants. The capital will fund commercialization of its RenovoCath device and completion of its Phase III TIGeR-PaC trial in pancreatic cancer, with management highlighting runway into 2027 and upcoming commercial expansion from trial sites transitioning to revenue-generating use.
Key Financial Metrics
Key Facts
- Raised $10 million in gross proceeds from a private placement of common stock and revenue milestone warrants
- Issued 10,638,790 shares (and pre-funded warrants) at $0.938 per share, with 50% warrant coverage exercisable at $1.751
- Warrants expire upon first quarter with $1.5M in gross product revenue or March 30, 2029, whichever comes first
- Proceeds to fund RenovoCath commercialization and Phase III TIGeR-PaC trial completion with data readout expected in 2027
- First nine months of 2025 generated ~$900,000 in RenovoCath sales; full commercial ramp expected as 16 trial sites transition to commercial use
Financial Impact
$10 million gross proceeds; $900,000 in RenovoCath revenue for first nine months of 2025
Risk Factors
- Revenue milestone warrants could incentivize short-term revenue recognition pressure
- No guarantee that trial sites will convert to paying customers or that commercial adoption will scale
- High dilution risk if warrants are exercised or additional financings are needed before cash-flow breakeven
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260378 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $1.27 | awaiting T+60 | — | $1.31 (+3.15%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.31 (+45.86%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.31 (−42.38%) |
May 26, 2026 21w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.31 (+43.01%) |
May 19, 2026 22w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.31 (+62.53%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.31 (+67.31%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.31 (+59.76%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.31 (+57.64%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.31 (+55.95%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.31 (+31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers